Cargando…

PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer

Reduced expression of both classical and desmosomal cadherins has been associated with different types of carcinomas, including prostate cancer. This study aims to provide a comprehensive view of the role and regulation of cell–cell adhesion in prostate cancer aggressiveness by examining the functio...

Descripción completa

Detalles Bibliográficos
Autores principales: Barber, Alison G, Castillo-Martin, Mireia, Bonal, Dennis M, Jia, Angela J, Rybicki, Benjamin A, Christiano, Angela M, Cordon-Cardo, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559037/
https://www.ncbi.nlm.nih.gov/pubmed/26033689
http://dx.doi.org/10.1002/cam4.463
_version_ 1782388709569593344
author Barber, Alison G
Castillo-Martin, Mireia
Bonal, Dennis M
Jia, Angela J
Rybicki, Benjamin A
Christiano, Angela M
Cordon-Cardo, Carlos
author_facet Barber, Alison G
Castillo-Martin, Mireia
Bonal, Dennis M
Jia, Angela J
Rybicki, Benjamin A
Christiano, Angela M
Cordon-Cardo, Carlos
author_sort Barber, Alison G
collection PubMed
description Reduced expression of both classical and desmosomal cadherins has been associated with different types of carcinomas, including prostate cancer. This study aims to provide a comprehensive view of the role and regulation of cell–cell adhesion in prostate cancer aggressiveness by examining the functional implications of both E-cadherin and Desmoglein 2 (DSG2). E-cadherin expression was first examined using immunofluorescence in 50 normal prostate tissues and in a cohort of 414 prostate cancer patients. Correlation and survival analyses were performed to assess its clinical significance. In primary prostate cancer patients, reduced expression of both E-cadherin and DSG2 is significantly associated with an earlier biochemical recurrence. Transgenic DU145 E-cadherin knockdown and constitutively active AKT overexpression lines were generated. Functional implications of such genetic alterations were analyzed in vitro and in vivo, the latter by using tumorigenesis as well as extravasation and metastatic tumor formation assays. We observed that loss of E-cadherin leads to impaired primary and metastatic tumor formation in vivo, suggesting a tumor promoter role for E-cadherin in addition to its known role as a tumor suppressor. Activation of AKT leads to a significant reduction in E-cadherin expression and nuclear localization of Snail, suggesting a role for the PI3K/AKT signaling pathway in the transient repression of E-cadherin. This reduced expression may be regulated by separate mechanisms as neither the loss of E-cadherin nor activation of AKT significantly affected DSG2 expression. In conclusion, these findings illustrate the critical role of cell–cell adhesion in the progression to aggressive prostate cancer, through regulation by the PI3K pathway.
format Online
Article
Text
id pubmed-4559037
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-45590372015-09-09 PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer Barber, Alison G Castillo-Martin, Mireia Bonal, Dennis M Jia, Angela J Rybicki, Benjamin A Christiano, Angela M Cordon-Cardo, Carlos Cancer Med Cancer Biology Reduced expression of both classical and desmosomal cadherins has been associated with different types of carcinomas, including prostate cancer. This study aims to provide a comprehensive view of the role and regulation of cell–cell adhesion in prostate cancer aggressiveness by examining the functional implications of both E-cadherin and Desmoglein 2 (DSG2). E-cadherin expression was first examined using immunofluorescence in 50 normal prostate tissues and in a cohort of 414 prostate cancer patients. Correlation and survival analyses were performed to assess its clinical significance. In primary prostate cancer patients, reduced expression of both E-cadherin and DSG2 is significantly associated with an earlier biochemical recurrence. Transgenic DU145 E-cadherin knockdown and constitutively active AKT overexpression lines were generated. Functional implications of such genetic alterations were analyzed in vitro and in vivo, the latter by using tumorigenesis as well as extravasation and metastatic tumor formation assays. We observed that loss of E-cadherin leads to impaired primary and metastatic tumor formation in vivo, suggesting a tumor promoter role for E-cadherin in addition to its known role as a tumor suppressor. Activation of AKT leads to a significant reduction in E-cadherin expression and nuclear localization of Snail, suggesting a role for the PI3K/AKT signaling pathway in the transient repression of E-cadherin. This reduced expression may be regulated by separate mechanisms as neither the loss of E-cadherin nor activation of AKT significantly affected DSG2 expression. In conclusion, these findings illustrate the critical role of cell–cell adhesion in the progression to aggressive prostate cancer, through regulation by the PI3K pathway. John Wiley & Sons, Ltd 2015-08 2015-05-29 /pmc/articles/PMC4559037/ /pubmed/26033689 http://dx.doi.org/10.1002/cam4.463 Text en © 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. http://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cancer Biology
Barber, Alison G
Castillo-Martin, Mireia
Bonal, Dennis M
Jia, Angela J
Rybicki, Benjamin A
Christiano, Angela M
Cordon-Cardo, Carlos
PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer
title PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer
title_full PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer
title_fullStr PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer
title_full_unstemmed PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer
title_short PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer
title_sort pi3k/akt pathway regulates e-cadherin and desmoglein 2 in aggressive prostate cancer
topic Cancer Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559037/
https://www.ncbi.nlm.nih.gov/pubmed/26033689
http://dx.doi.org/10.1002/cam4.463
work_keys_str_mv AT barberalisong pi3kaktpathwayregulatesecadherinanddesmoglein2inaggressiveprostatecancer
AT castillomartinmireia pi3kaktpathwayregulatesecadherinanddesmoglein2inaggressiveprostatecancer
AT bonaldennism pi3kaktpathwayregulatesecadherinanddesmoglein2inaggressiveprostatecancer
AT jiaangelaj pi3kaktpathwayregulatesecadherinanddesmoglein2inaggressiveprostatecancer
AT rybickibenjamina pi3kaktpathwayregulatesecadherinanddesmoglein2inaggressiveprostatecancer
AT christianoangelam pi3kaktpathwayregulatesecadherinanddesmoglein2inaggressiveprostatecancer
AT cordoncardocarlos pi3kaktpathwayregulatesecadherinanddesmoglein2inaggressiveprostatecancer